The New York Times reports that Topamax, manufactured by Johnson & Johnson, has been linked to birth defects, such as a higher risk of developing cleft lips and palates, genital malformations and cranial malformations.
Topamax is an anti-seizure and migraine drug used in the treatment of migraines and epilepsy. It is also used in the weight-loss drug Qnexa.
Infants exposed to the dangerous drug during their mother’s first trimester of pregnancy had a 3 times higher rate of mouth defects than those whose mothers took other seizure medications.
The FDA notes “doctors should think carefully before prescribing the drug to women of childbearing age and ‘alternative medications that have a lower risk of birth defects should be considered.'”